Capricor Therapeutics Inc
Performance History
| Key Stats | |
|---|---|
| Open | $3.35 |
| Prev. Close | $3.30 |
| EPS | -1.21 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 7, 2023 |
| Dividend Yield % | - |
| Market Cap | $102.84M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 3.25 | 3.53 |
| 52 Week Range | 2.68 | 8.22 |
| Ratios | |
|---|---|
| P/B Ratio | 7.73 |
| Revenue | $14.04M |
| Operating M. % | -110.97% |
| Earnings | -$29.24M |
| Earnings Growth % | 288.66% |
| EBITDA Margin % | -212.92% |
| ROE % | -428.87% |
| EPS | -1.21 |
Score Breakdown
All Score (70 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| CAPR | MARKET | |
|---|---|---|
| Value | 69 | 40 |
| Quality | 65 | 45 |
| Ownership | 16 | 39 |
| Growth | 59 | 45 |
| Dividends | - | 31 |
All Score (70 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Capricor Therapeutics Inc (CAPR)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Linda Marbán Ph.D.
- Headquarters
- San Diego
- Employees
- 74
Keep an eye on Capricor Therapeutics Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.